UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
| |||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
On March 2, 2022, Aytu BioPharma, Inc. (“Aytu” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Canaccord Genuity LLC (“Canaccord”), relating to the issuance and sale to an institutional investor of (i) 3,030,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share, (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 3,030,000 shares of common stock, and (iii) common stock purchase warrants (the “Common Warrants” and, together with the Shares and the Pre-Funded Warrants, the “Securities”) to purchase up to 6,666,000 shares of common stock (the “Offering”). The Shares and the Pre-Funded Warrants were each sold in combination with corresponding Common Warrants, with one Common Warrant to purchase 1.1 shares of common stock for each Share or each Pre-Funded Warrant sold.
The Pre-Funded Warrants will have an exercise price of $0.0001 per share of common stock and the Common Warrants will have an exercise price of $1.30 per share of common stock. The Pre-Funded Warrants will be immediately exercisable and remain exercisable until exercised, while the Common Warrants will be exercisable six months after the date of issuance and will have a term of five years from the date of exercisability. The aggregate offering price for each Share and an accompanying Common Warrant was $1.25. The aggregate offering price for each Pre-Funded Warrant and an accompanying Common Warrant was $1.2499.
A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. A holder of Common Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants or Common Warrants may increase or decrease this percentage to a percentage not in excess of 9.99% by providing at least 61 days’ prior notice to the Company.
The offer and sale of the Securities was made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-259862) (the “Registration Statement”), which was declared effective by the Securities and Exchange Commission on October 7, 2021, as supplemented by a prospectus supplement.
The Underwriting Agreement contains customary representations, warranties and covenants made by the Company. It also provides for customary indemnification by each of the Company and Canaccord for losses or damages arising out of or in connection with the Offering, including for liabilities under the Securities Act of 1933, other obligations of the parties and termination provisions. In addition, pursuant to the terms of the Underwriting Agreement, directors and executive officers of the Company have entered into lock-up agreements with Canaccord that generally prohibit during a 120-day period following the entry into the Underwriting Agreement, without the prior written consent of Canaccord, the sale, transfer or other disposition of securities of the Company.
The closing of the Offering is expected to occur on March 7, 2022. Aytu received approximately $6.7 million of net proceeds, after deducting underwriting discounts and estimated offering expenses.
The form of Pre-Funded Warrant and Common Warrant are filed as Exhibits 4.1 and 4.2, respectively, and are incorporated by reference into this Current Report on Form 8-K. The foregoing description of such documents is qualified in its entirety by reference to the full text thereof.
The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement, which is attached as Exhibit 1.1 to this Current Report on Form 8-K and incorporated by reference herein.
In connection with the Offering, the Company is filing a legal opinion and consent as Exhibit 5.1 and 23.1, respectively, to this Current Report on Form 8-K, each of which is incorporated by reference in its entirety into the Registration Statement.
Item 7.01 Regulation FD Disclosure.
On Company issued a press release on March 2, 2022 announcing the pricing of the Offering, which is attached as Exhibit 99.1 to this report.
Item 9.01 Financial Statements and Exhibits.
(d) | Exhibits. |
Exhibit |
| Description |
1.1 | ||
4.1 | ||
4.2 | ||
5.1 | ||
23.1 | ||
99.1* | ||
104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) |
* In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.